Source comparison
Thymosin Alpha-1 Protocol vs Other MCAS/CIRS Peptides: Full Comparison
Multiple peptides show promise in MCAS/CIRS treatment. But they address different aspects of the pathology and aren't interchangeable. Thymosin Alpha-1 T-cell modulation, Th1/Th2 rebalancing, Treg upregulation 1.6mg SQ twice weekly × 12–16 weeks Immune dysregu
This comparison does not assign a generated winner or score.
- Multiple peptides show promise in MCAS/CIRS treatment. But they address different aspects of the pathology and aren't interchangeable.
- Thymosin Alpha-1
- T-cell modulation, Th1/Th2 rebalancing, Treg upregulation
- 1.6mg SQ twice weekly × 12–16 weeks
- Immune dysregulation, low NK function, elevated TGF-β1
- Multiple CIRS case series; Phase III data in hepatitis/cancer
- Gold standard for immune rebalancing in biotoxin illness. Mechanism directly targets cytokine lock
- BPC-157
- Gut barrier repair, angiogenesis, VEGF modulation
- 250–500mcg SQ daily × 4–8 weeks
- Gut permeability, leaky gut as MCAS driver
- Rodent models only; no human RCTs
- Useful adjunct for gut-driven MCAS but not a substitute for immune modulation
- LL-37 (Cathelicidin)
- Antimicrobial peptide, biofilm disruption, immune signaling
- 2–4mg SQ 3×/week × 8 weeks
- Concurrent Lyme/co-infections, biofilm-related pathogen persistence
- In vitro antimicrobial data; limited human studies
- Essential when infection load blocks Tα1 response. Sequence LL-37 first, then Tα1
- Semax
- Neuroprotection, BDNF upregulation, cognitive support
- 300–600mcg intranasal daily
- Brain fog, cognitive dysfunction in CIRS
- Russian neurology literature; minimal Western clinical data
- Symptomatic relief for neurotoxicity but doesn't address root immune dysregulation
- Vasoactive Intestinal Peptide (VIP)
- Neuroinflammation modulation, cytokine regulation in CNS
- 50mcg intranasal 4×/day × 6 months
- CIRS patients failing cholestyramine/Tα1, severe neurotoxicity
- Dr. Shoemaker's clinical protocols; no RCT data
- Second-line therapy after Tα1. Expensive, requires compounding, but effective for refractory cases
- Thymosin alpha-1 is the foundational peptide because it addresses the core immune dysregulation that drives both MCAS and CIRS. Real Peptides provides research-grade thymosin alpha-1 with batch-specific amino-acid sequencing verification. Critical because even small sequence variations in peptide synthesis can reduce receptor binding affinity and clinical efficacy.